FORMULATION AND EVALUATION OF BUCCAL PATCH CONTAINING ACECLOFENAC
U. D. Shivhare, P. B. Suruse, S. S. Varvandkar
College of Pharmacy, Wanadongri, Hingna Road, Nagpur-441 110. (M.S.) India
Keywords: Aceclofenac, Mucoadhesion, Buccal patch
The main objective of the present study was to improve bioavailability of Aceclofenac and decrease the frequency of dosage form administration by sustained release formulation of the drug from the mucoadhesive drug delivery system. Aceclofenac belongs to the drug class known as NSAIDs. It is normally indicated for the treatment of dental pain, rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is selective cox-2 inhibitor. It has an extensive and highly variable hepatic first pass metabolism following oral administration having half life of 4 h. The usual dose of Aceclofenac is 100 mg twice daily with systemic bioavailability of 40- 50% due to extensive “first-pass” metabolism and has a narrow absorption window. These characteristics make Aceclofenac a suitable drug candidate for mucoadhesive drug delivery system. Aceclofenac containing mucoadhesive buccal patches were prepared by solvent evaporation method. The buccal patches were formulated using polymers HPMC E-15 and Eudragit RL 100 alone and in combination. The buccal patches were evaluated for weight variation, thickness, folding endurance, content uniformity, swelling index, in-vitro diffusion study, in-vitro residence time and in-vitro Mucoadhesive strength. Among five formulations using factorial approach F2 showed maximum release 92.35% upto 8 h.
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits